Impact Of Chronic Hepatitis C Infectionand Liver Metastasis On Survival Outcome Of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (nsclc) Patient Treated With First-Line Gefetinib In Real-World Practice

被引：0
|
作者：
Yao, Z. -H.
Liao, W. -Y.
Ho, C. -C.
Chen, K. -Y.
Shih, J. -Y.
Chen, J. -S.
Lin, Z. -Z.
Lin, C. -C.
Yang, J. -H.
Yu, C. -J.
机构：
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2016年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4272
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Real-world disease burden and outcomes of brain metastases in EGFR mutation-positive non-small-cell lung cancer
    Nadler, Eric
    Espirito, Janet L.
    Pavilack, Melissa
    Baidoo, Bismark
    Fernandes, Ancilla
    FUTURE ONCOLOGY, 2020, 16 (22) : 1575 - 1584
  • [12] Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer
    Nazha, Bassel
    Yang, James C-H
    Owonikoko, Taofeek K.
    FUTURE ONCOLOGY, 2021, 17 (08) : 965 - 977
  • [13] Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer
    Reungwetwattana, Thanyanan
    Rohatgi, Nitesh
    Mok, Tony S.
    Prabhash, Kumar
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (03): : 161 - 171
  • [14] Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer
    Yang, Szu-Chun
    Lin, Chien-Chung
    Lai, Wu-Wei
    Chang, Sheng-Mao
    Hwang, Jing-Shiang
    Su, Wu-Chou
    Wang, Jung-Der
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [15] NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer
    Dillon, Bernice
    Naidoo, Bhash
    Knight, Helen
    Clark, Peter
    LANCET ONCOLOGY, 2012, 13 (08): : 764 - 765
  • [16] First-line treatment and overall survival in EGFR mutation-positive advanced non-small cell lung cancer: a national cohort study
    Huang, L. -y.
    Chang, H. -p.
    Chang, R. -y.
    Tai, H. -y.
    Huang, Y. -w.
    Lee, P. -c.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (20) : 7632 - 7640
  • [17] Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation
    Imamura, Fumio
    Kimura, Madoka
    Yano, Yukihiro
    Mori, Masahide
    Suzuki, Hidekazu
    Hirashima, Tomonori
    Ihara, Shouichi
    Komuta, Kiyoshi
    Shiroyama, Takayuki
    Nagatomo, Izumi
    Kumagai, Toru
    FUTURE ONCOLOGY, 2020, 16 (21) : 1537 - 1546
  • [18] Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)
    Sakata, Yoshihiko
    Sakata, Shinya
    Oya, Yuko
    Tamiya, Motohiro
    Suzuki, Hidekazu
    Shibaki, Ryota
    Okada, Asuka
    Kobe, Hiroshi
    Matsumoto, Hirotaka
    Yokoi, Takashi
    Sato, Yuki
    Uenami, Takeshi
    Saito, Go
    Tsukita, Yoko
    Inaba, Megumi
    Ikeda, Hideki
    Arai, Daisuke
    Maruyama, Hirotaka
    Hara, Satoshi
    Tsumura, Shinsuke
    Morinaga, Jun
    Sakagami, Takuro
    EUROPEAN JOURNAL OF CANCER, 2021, 159 : 144 - 153
  • [19] BUDGET IMPACT ANALYSIS OF ERLOTIB AS THE FIRST-LINE THERAPY OF ADVANCED EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER IN VIETNAM
    Tran, T. T.
    Nguyen, T.
    VALUE IN HEALTH, 2016, 19 (03) : A142 - A143
  • [20] Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)
    Sakata, Yoshihiko
    Saito, Go
    Sakata, Shinya
    Oya, Yuko
    Tamiya, Motohiro
    Suzuki, Hidekazu
    Shibaki, Ryota
    Okada, Asuka
    Yokoyama, Toshihide
    Matsumoto, Hirotaka
    Otsuki, Taiichiro
    Sato, Yuki
    Junji, Uchida
    Tsukita, Yoko
    Inaba, Megumi
    Ikeda, Hideki
    Arai, Daisuke
    Maruyama, Hirotaka
    Hara, Satoshi
    Tsumura, Shinsuke
    Morinaga, Jun
    Sakagami, Takuro
    LUNG CANCER, 2023, 186
12345